Kubient (KBNT) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock KBNT vs. KLDO, ALFIW, APCXW, ARBEW, AOGOW, AOGOU, AUROW, AVPTW, BNIXW, and BNIXRShould you be buying Kubient stock or one of its competitors? The main competitors of Kubient include Kaleido Biosciences (KLDO), Alfi (ALFIW), AppTech Payments (APCXW), Arbe Robotics (ARBEW), Arogo Capital Acquisition (AOGOW), Arogo Capital Acquisition (AOGOU), Aurora Innovation (AUROW), AvePoint (AVPTW), Bannix Acquisition (BNIXW), and Bannix Acquisition (BNIXR). These companies are all part of the "computer software" industry. Kubient vs. Its Competitors Kaleido Biosciences Alfi AppTech Payments Arbe Robotics Arogo Capital Acquisition Arogo Capital Acquisition Aurora Innovation AvePoint Bannix Acquisition Bannix Acquisition Kubient (NASDAQ:KBNT) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap computer software companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Does the media favor KBNT or KLDO? In the previous week, Kubient's average media sentiment score of 0.00 equaled Kaleido Biosciences'average media sentiment score. Company Overall Sentiment Kubient Neutral Kaleido Biosciences Neutral Do institutionals and insiders hold more shares of KBNT or KLDO? 13.9% of Kubient shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 22.3% of Kubient shares are owned by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, KBNT or KLDO? Kubient has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Kaleido Biosciences has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Is KBNT or KLDO more profitable? Company Net Margins Return on Equity Return on Assets KubientN/A N/A N/A Kaleido Biosciences N/A N/A N/A Which has better earnings & valuation, KBNT or KLDO? Kubient has higher revenue and earnings than Kaleido Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKubient$1.17M0.00-$13.62MN/AN/AKaleido Biosciences$1.10M0.00-$95.48M-$2.24N/A SummaryKubient beats Kaleido Biosciences on 4 of the 5 factors compared between the two stocks. Get Kubient News Delivered to You Automatically Sign up to receive the latest news and ratings for KBNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KBNT vs. The Competition Export to ExcelMetricKubientComputer integrated systems design IndustryBusiness SectorNASDAQ ExchangeMarket Cap$1K$1.21B$13.21B$9.02BDividend YieldN/A2.62%2.68%4.08%P/E RatioN/A2.2028.5620.04Price / SalesN/A0.3639.79108.84Price / CashN/A9.4426.0728.59Price / BookN/A3.436.275.55Net Income-$13.62M$223.79M$188.15M$248.49M Kubient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KBNTKubientN/AN/AN/AN/A$1K$1.17M0.0040KLDOKaleido BiosciencesN/A$0.00flatN/AN/A$4K$1.10M0.0080ALFIWAlfiN/AN/AN/AN/A$0.00$200.68K0.0040APCXWAppTech PaymentsN/A$0.08flatN/A-73.7%$0.00$276K0.0020Gap UpARBEWArbe RoboticsN/A$0.24-21.3%N/A+2.9%$0.00$671K0.00120Positive NewsAOGOWArogo Capital AcquisitionN/A$0.03flatN/AN/A$0.00N/A0.00N/AAOGOUArogo Capital AcquisitionN/A$8.50flatN/AN/A$0.00N/A0.00N/AAUROWAurora InnovationN/A$0.82-5.7%N/A+245.5%$0.00$2M0.001,700Gap DownAVPTWAvePointN/A$7.05-9.3%N/A+364.2%$0.00$349.01M0.001,930Positive NewsBNIXWBannix AcquisitionN/A$0.06+27.3%N/AN/A$0.00N/A0.003Gap UpBNIXRBannix AcquisitionN/A$0.24+0.8%N/A+121.0%$0.00N/A0.003Gap Down Related Companies and Tools Related Companies Kaleido Biosciences Alternatives Alfi Alternatives AppTech Payments Alternatives Arbe Robotics Alternatives Arogo Capital Acquisition Alternatives Arogo Capital Acquisition Alternatives Aurora Innovation Alternatives AvePoint Alternatives Bannix Acquisition Alternatives Bannix Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KBNT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kubient, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kubient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.